Single-use Chromatography Systems Market Size, Share, Trends, Industry Analysis Report

Market Outlook

The global single-use chromatography systems market, valued at USD 1.8 billion in 2025, is projected to reach USD 2.0 billion in 2026 and USD 6.3 billion by 2035, representing a CAGR of 13.7% during the forecast period from 2026 to 2035.

To learn more about this report, request a free sample copy

Market Report: Key Takeaways

Market Size & Trends

• With respect to the scale of operation, commercial scale currently holds around 80% of the market share.
• In terms of end users, pharma and biopharmaceutical companies are primarily contributing to the overall market size as these companies are the primary developers of high-volume biologics like monoclonal antibodies and recombinant proteins.
• In terms of key geographical region, Europe currently holds the highest market share.

Key Market Statistics

• Market Size in 2026: $2.0 billion
• Estimated Market Size in 2035: $6.3 billion
• CAGR (2026-2035): 13.7%
• Europe: Largest market in 2026
• Asia-Pacific: Fastest growing region

Market Introduction

Single-use chromatography systems are becoming an increasingly important part of modern biopharmaceutical purification workflows, as manufacturers look for faster, cleaner, and more flexible alternatives to conventional stainless-steel chromatography infrastructure. This shift is being supported by the continued growth of biologics and advanced therapies. As biologics pipelines expand, demand is increasing for chromatography platforms that can support rapid process development, smaller batch sizes, contamination control, and faster transition from clinical to commercial manufacturing.

The broader single-use bioprocessing ecosystem is also maturing, which is creating a favorable environment for single-use chromatography adoption. A 2025 BioPlan survey cited by BioProcess Online indicated that more than 90% of manufacturing facilities surveyed were already using single-use systems in at least some part of their operations, suggesting that single-use technologies have become a standard element of modern biomanufacturing rather than a niche option. Further, in June 2025, Sartorius Stedim Biotech completed a major capacity expansion in France, nearly doubling cleanroom space to around 9,000 square meters to meet growing demand for single-use bioprocessing solutions.

Within downstream processing, single-use technologies are increasingly being used across filtration, buffer handling, fluid transfer, storage, and selected chromatography applications. Recent assessments indicate that most downstream processing steps in single-use facilities can now be performed using disposable flow paths, filtration assemblies and holding vessels. At the clinical scale, Protein A chromatography can also be conducted using pre-packed, single-use column systems. However, large-scale chromatography remains one of the slower downstream steps to transition fully to single-use formats, which creates both a challenge and a growth opportunity for suppliers developing scalable single-use chromatography systems.

Driven by rising biologics approvals, growing CDMO capacity, increasing use of single-use bioprocessing infrastructure, and the need to reduce turnaround time in purification workflows, the single-use chromatography systems market is expected to witness sustained growth during the forecast period.

Single-Use Chromatography Value Chain and Supplier Ecosystem

Market Segmentation

Based on the research, we have segmented the single-use chromatography systems market into scale of operation, end user, and key geographical regions.

By Scale of Operation

• Preclinical and Clinical
• Commercial

By End User

• Pharma and Biopharmaceutical Companies
• CROs and CMOs
• Other End Users

By Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Rest of the World

Single-Use Chromatography Systems Market Key Insights

What are the Key Drivers for Single-Use Chromatography Systems Market Growth?

• Rising Demand for Biologics and Advanced Therapies: The growth of biologics, biosimilars, vaccines, recombinant proteins, monoclonal antibodies, and cell and gene therapies is increasing demand for efficient downstream purification technologies. In 2025, the US FDA's CDER approved 46 novel drugs, reflecting continued innovation in drug development and supporting the need for flexible bioprocessing infrastructure. Single-use chromatography systems help manufacturers purify complex biologics with faster setup, lower contamination risk, and reduced turnaround time.
• Expansion of Advanced Downstream Purification Capacity: The growing scale of biologics manufacturing is increasing demand for advanced downstream purification infrastructure. In 2026, Aurobindo Pharma's subsidiary TheraNym announced plans to invest USD 150–175 million in a new biologic drug substance facility for MSD, including mammalian cell culture bioreactors and advanced downstream purification infrastructure. This reflects continued investment in biologics manufacturing capacity, which supports demand for chromatography-based purification technologies.

What are the Main Challenges to Market Growth?

• Scale-Up Limitations for Commercial Manufacturing: One of the major challenges for single-use chromatography systems is limited scalability in large-volume commercial biologics production. Pre-packed single-use columns are highly useful in process development and clinical-scale manufacturing, but they may not always match the capacity, robustness, and repeated-use economics of large stainless-steel chromatography columns. Cytiva specifies that pre-packed single-use columns have historically been limited in scale due to handling, transportation, cost, and limited cycle-use capabilities at larger manufacturing scales.
• Extractables and Leachables Risk: Because single-use chromatography systems use plastic and polymeric product-contact materials, manufacturers must evaluate the risk of extractables and leachables entering the process stream. This is especially important for biologics, vaccines, and advanced therapies where product quality and patient safety are highly sensitive. BioPhorum highlighted in 2025 that managing extractables and leachables from single-use manufacturing systems remains a critical risk-assessment area, particularly for advanced therapy medicinal products, and that broader consensus between industry and regulators is still developing.

Recent Developments in Single-Use Chromatography Systems Market

• In April 2026, Merck completed the acquisition of JSR Life Sciences' chromatography business, adding Amsphere Protein A resins and advanced Protein A chromatography capabilities to its downstream processing portfolio. The acquisition expands scalable antibody purification tools for development through commercial manufacturing workflows.
• In March 2026, W. L. Gore & Associates expanded its membrane chromatography offering with next-generation affinity solutions developed with customized ligand partners. The products target purification productivity and scalability for cell and gene therapies, specialized antibody therapies, and other bioprocessing applications.
• In December 2025, Repligen launched AVIPure HiPer AAV9 and AAV8 affinity resins and HiPer QA anion exchange resin for new modality workflows. The resins are designed to improve viral vector chromatography productivity and process robustness in gene therapy manufacturing.

Industry Experts on Single-Use Chromatography Systems Market

Driven by growing adoption of automated, single–use chromatography platforms that integrate streamlined sample handling and process controls to improve run–to–run consistency and minimize manual intervention, the single–use chromatography systems market is poised for significant growth in the coming years.

Hélène Pora (VP Technical Communication & Regulatory Strategy, Pall Biotech) stated: "For every manufacturer it is critical to evaluate processes and see where they can take the greatest advantage of the single-use technologies from the earliest point, while also considering the scalability of the process(es) in question. We suggest taking a quality by design (QbD) approach to designing and implementing proven, market-driven processes that are supported by the right products and services."

Discussions with multiple stakeholders in this domain influenced the opinions and insights presented in this study. The single-use chromatography systems market report includes detailed transcripts of interviews conducted with the following third-party discussions:

• Chief Operating Officer, Small Company, Australia
• VP Technical Communication & Regulatory Strategy, Large Company, New York
• Head of Advanced Materials and Processing, Very Large Company, Germany
• Head of Application Labs, Large Company, Denmark
• Senior Product Manager, Very Large Company, US
• Market Manager, Mid-sized Company, US
• Product Line Manager, Mid-sized Company, Austria
• Product Line Manager, Mid-sized Company, Austria
• Application Specialist for Stem Cells, Large Company, Denmark
• Former Senior Vice President Marketing & Product Management, Very Large Company, Denmark

Market Share Insights

Which Scale of Operation Accounts for the Largest Share in the Single-Use Chromatography Systems Market?

• In 2026, the commercial scale segment occupies the highest market share (around 80%) owing to the large-volume downstream purification requirements associated with the commercial production of biologics, biosimilars, vaccines, and recombinant proteins. Once a biologic receives regulatory approval, manufacturers operate multiple production campaigns annually, requiring chromatography systems that offer high throughput, rapid product changeovers, and minimal downtime.
• The preclinical and clinical-scale segment is expected to grow at a significant pace during the forecast period owing to the rapid expansion of biologics, cell and gene therapies, antibody-drug conjugates (ADCs), mRNA therapeutics, and other pipeline products entering early-stage development. Biopharmaceutical companies increasingly favor single-use chromatography systems during process development and clinical manufacturing because they enable rapid process optimization, smaller production batches, and quick transition between multiple drug candidates without extensive cleaning validation.

Regional Analysis: Which Regions are Showing the Fastest Growth in the Single-Use Chromatography Systems Market?

Europe: Dominating the Market by Securing the Highest Share

According to our projections, Europe holds the largest share of the single-use chromatography systems market owing to its strong biopharmaceutical manufacturing base, early adoption of single-use bioprocessing technologies, and the presence of leading technology suppliers. The region is home to globally recognized manufacturers such as Sartorius (Germany), Cytiva (Sweden), Merck KGaA (Germany), and Pall Corporation (European operations), which have driven innovation and widespread commercialization of disposable downstream purification technologies.

Europe also hosts a large number of biologics manufacturers and CDMOs, including Lonza, Rentschler Biopharma, Boehringer Ingelheim, and Recipharm, which increasingly rely on single-use chromatography systems to support flexible, multi-product manufacturing of monoclonal antibodies, vaccines, and advanced therapies. Furthermore, the region has been at the forefront of implementing continuous bioprocessing and modular manufacturing strategies, driving demand for disposable purification solutions that reduce cleaning validation requirements and manufacturing downtime.

Asia-Pacific: Growing at the Highest CAGR

The Asia-Pacific single-use chromatography systems market is expected to grow at a significant pace during the forecast period owing to the rapid expansion of biologics manufacturing capacity, increasing investment in biosimilars and advanced therapeutics, and strong government initiatives to strengthen domestic biopharmaceutical production. Countries such as China, South Korea, India, and Singapore are investing heavily in large-scale manufacturing facilities for monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies, creating substantial demand for flexible single-use purification technologies. For example, China's 14th Five-Year Plan for the Development of the Bioeconomy prioritizes high-end biomanufacturing and domestic biologics production, while South Korea's K-Bio Strategy aims to establish the country as a global biomanufacturing hub by expanding biologics manufacturing capacity and CDMO capabilities. India is also accelerating adoption of advanced bioprocessing technologies through the National BioPharma Mission, which supports biologics innovation and manufacturing infrastructure.

Scope of Single-Use Chromatography Systems Market Report